On November 24, 2025, Rutgers University announced a significant upcoming clinical trial focused on advancing care for pregnancies complicated by hypertension and/or diabetes. The study, titled “MOM-HD,” is designed to assess the effectiveness of mobile-based obstetric monitoring compared to standard care in improving outcomes for these high-risk pregnancies. Clinical and regulatory professionals, particularly those involved in maternal health technologies, may find these developments critical to future care pathways.
In this article:
- What changed?
- Who is involved?
- What does the study examine?
- Frequently Asked Questions
- Conclusion
- Disclaimer
- Full Announcement and Link
What changed?
The announcement revealed an innovative approach to monitoring high-risk pregnancies through the MOM-HD initiative. This clinical trial has not yet begun recruiting participants but aims to test whether mobile-based intervention methods deliver better clinical outcomes for gestational diabetes and hypertensive disorders during pregnancy.
The trial represents a shift towards harnessing mobile platforms as tools for real-time health monitoring. Such a model could reduce delays in care, improve adherence to clinical guidelines, and potentially enhance safety for both mothers and their unborn children.
Who is involved?
The study is sponsored by Rutgers University in collaboration with Dhulikhel Hospital and the Institute for Implementation Science and Health. As a multi-center trial, the collaborative involvement of stakeholders emphasizes the scalability and potential global impact of mobile obstetric monitoring systems, especially in resource-limited settings.
Both academic and hospital partners are likely to oversee technical implementation, clinical protocol adherence, and the integration of findings into broader healthcare guidelines.
What does the study examine?
The MOM-HD trial focuses on two patient groups with distinct conditions: gestational diabetes and hypertensive disorders of pregnancy. These complications are among the leading causes of adverse maternal and perinatal outcomes worldwide.
The interventions under evaluation are:
- MOM-HD (Behavioral): A mobile-based platform that enables continuous obstetric health monitoring, incorporating behavioral health strategies to support patients.
- Standard Care (Control): Patients in this group will receive conventional, clinic-based obstetric care.
The study intends to compare adherence rates, maternal and fetal health outcomes, and the feasibility of mobile monitoring to traditional methods of care delivery.
If successful, the findings could inform updates to clinical best practices, especially in underserved populations where access to in-person care is limited. Such evidence could pave the way for regulatory approvals and broader adoption of mobile health technologies, aligning with an ever-evolving healthcare landscape.
Frequently Asked Questions
- When will the study start recruiting?
The trial is currently marked as “Not yet recruiting” on ClinicalTrials.gov. Prospective updates will be available on the provided study link. - What conditions does the trial target?
The trial is focused on gestational diabetes and hypertensive disorders in pregnancy. - What is the primary intervention being studied?
The intervention examined is the MOM-HD mobile-based obstetric monitoring system.
Conclusion
The MOM-HD study reflects a growing interest in digital health solutions to address maternal health challenges. The use of mobile platforms has the potential to transform care delivery for high-risk pregnancies, reducing disparities and enhancing outcomes. Clinical, quality, and regulatory teams should monitor this trial closely as its findings may affect future standards of care or regulatory requirements for maternal-fetal health technologies.
Disclaimer
This content is intended for informational purposes for professionals in the medical, regulatory, or clinical sectors. It does not constitute legal or clinical advice. Please consult official trial documentation for detailed insights.
Full Announcement and Link
For full information about the announcement, see the link below.
https://clinicaltrials.gov/study/NCT07243886?term=medical+device